Neoadjuvant Chemotherapy for Operable Breast Cancer: Individualizing Locoregional and Systemic Therapy

被引：13
|
作者：
Bear, Harry D. [1 ]
机构：
[1] Virginia Commonwealth Univ, Div Surg Oncol, Dept Surg, Massey Canc Ctr, Richmond, VA 23298 USA
来源：
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA | 2010年 / 19卷 / 03期
关键词：
Breast cancer; Neoadjuvant; Chemotherapy; Breast conservation surgery; Sentinel lymph nodes; LYMPH-NODE BIOPSY; PATHOLOGICAL COMPLETE RESPONSE; SURGICAL ADJUVANT BREAST; INVASIVE LOBULAR CARCINOMA; PROJECT PROTOCOL B-27; ROUTINE AXILLARY DISSECTION; EPIRUBICIN PLUS DOCETAXEL; III RANDOMIZED GEPARTRIO; PREOPERATIVE CHEMOTHERAPY; SENTINEL-NODE;
D O I：
10.1016/j.soc.2010.04.001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Neoadjuvant chemotherapy (NAG) is being used with increasing frequency in the multidisciplinary care of women with breast cancer. NAG can increase the chances for successful breast conservation and may decrease the need for axillary node dissection in selected patients. Some patients with chemoresistant tumors may benefit more from hormonal neoadjuvant therapy. The greatest potential for this approach is to predict responses of different breast cancers to therapy based on molecular profiles. This will accelerate better understanding of breast cancer biology and progress toward improved and more individualized therapy.
引用
收藏
页码：607 / +
页数：22
相关论文
共 50 条
  • [1] Neoadjuvant Therapy for Early-Stage Breast Cancer: A Model for Individualizing Outcomes and Tailoring Locoregional and Systemic Therapy
    Mamounas, Eleftherios P.
    [J]. ONCOLOGY-NEW YORK, 2015, 29 (11): : 839 - +
  • [2] Neoadjuvant chemotherapy for operable breast cancer
    Mieog, J. S. D.
    van der Hage, J. A.
    de Velde, C. J. H. van
    [J]. BRITISH JOURNAL OF SURGERY, 2007, 94 (10) : 1189 - 1200
  • [3] Neoadjuvant chemotherapy in operable breast cancer
    Giardina, G
    Chini, C
    Fagnoni, E
    Pigni, A
    Membrini, F
    Masera, LR
    Proserpio, I
    Martinelli, B
    Pinotti, G
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 44 - 44
  • [4] Locoregional therapy in breast cancer patients treated with neoadjuvant chemotherapy
    Murchison, Sonja
    Truong, Pauline
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (08) : 865 - 875
  • [5] Neoadjuvant chemotherapy in operable breast cancer: The pros
    Mamounas, Eleftheriors R.
    [J]. BREAST CARE, 2006, 1 (06) : 348 - 351
  • [6] Neoadjuvant chemotherapy for primary operable breast cancer
    Halberg, Anne Krag
    Gravesen, Charlotte Dahl
    Cold, Soren
    Jensen, Jeanette Dupont
    [J]. DANISH MEDICAL JOURNAL, 2020, 67 (12):
  • [7] NEOADJUVANT CHEMOTHERAPY IN OPERABLE BREAST-CANCER
    SCHOLL, SM
    ASSELAIN, B
    PALANGIE, T
    DORVAL, T
    JOUVE, M
    GIRALT, EG
    VILCOQ, J
    DURAND, JC
    POUILLART, P
    [J]. EUROPEAN JOURNAL OF CANCER, 1991, 27 (12) : 1668 - 1671
  • [8] Prognostic Factors for Locoregional Recurrence in Operable Breast Cancer Patients Treated with Preoperative Systemic Chemotherapy
    Jung, S-Y
    Min, S. Y.
    Lee, S. J.
    Park, C.
    Kwon, Y.
    Kim, E-A
    Ko, K. L.
    Lee, K. S.
    Park, I. H.
    Jeong, J.
    Shin, K. H.
    Lee, S.
    Kim, S. W.
    Kang, H-S
    Ro, J.
    [J]. CANCER RESEARCH, 2009, 69 (24) : 569S - 569S
  • [9] Neoadjuvant Versus Adjuvant Systemic Therapy for Operable Breast Cancer Equivalent Outcomes?
    Smith, Barbara L.
    [J]. ANNALS OF SURGERY, 2013, 257 (02) : 180 - 181
  • [10] Locoregional recurrence and survival of breast-conserving surgery compared to mastectomy following neoadjuvant chemotherapy in operable breast cancer
    Lv, Fa-you
    Mo, Zongming
    Chen, Binjie
    Huang, Zhen
    Mo, Qinguo
    Tan, Qixing
    [J]. FRONTIERS IN ONCOLOGY, 2024, 14
12345